Rejection after simultaneous pancreas-kidney transplantation.

Department of Surgery, University of Munich, Grosshadern, Marchioninistr. 15, D-81377 Munich, Germany.
Nephrology Dialysis Transplantation (Impact Factor: 3.37). 06/2005; 20 Suppl 2:ii11-7, ii62. DOI: 10.1093/ndt/gfh1077
Source: PubMed

ABSTRACT Simultaneous pancreas-kidney (SPK) transplantation is an accepted therapy for type 1 diabetic patients with end-stage renal disease. This study analyses the occurrence of rejection episodes in patients undergoing SPK.
The study population was obtained from 205 patients enrolled in the Euro-SPK 001 study and randomized to receive tacrolimus- (n = 103) or cyclosporin microemulsion (ME)-based (n = 102) immunosuppressive therapy. All patients received concomitant antibody induction therapy, mycophenolate mofetil and short-term corticosteroids.
After 3 years of follow-up, rejection episodes occurred in 41 patients receiving tacrolimus and in 51 patients receiving cyclosporin-ME. The majority of first rejection episodes in both groups occurred during the first 6 months (93 and 90%, respectively) and in most cases were treated with corticosteroids alone (88 vs 90%). Actuarial rejection-free kidney and/or pancreas graft survival was similar for tacrolimus (54%) and cyclosporin-ME (44%). Human leukocyte antigen (HLA) compatibility (P = 0.003) and graft vessel extension (P = 0.000001) had a significant influence on rejection-free graft survival. Also, rejection influenced pancreas graft survival (P = 0.01), and pancreas graft loss due to rejection influenced patient survival (P = 0.02). In the intent-to-treat analysis of early rejection, significantly fewer tacrolimus- than cyclosporin-ME-treated patients had (i) more than one rejection episode (11 out of 40 vs 24 out of 47; P = 0.03); (ii) first moderate to severe rejection (one out of 40 vs 12 out of 47; P = 0.004); and (iii) refractory rejection (two out of 40 vs 10 out of 47; P = 0.03). Pancreas survival was lower in late rejectors (53%) than non-rejectors (86%; P = 0.002). Also, serum creatinine was highest in late rejectors.
Tacrolimus-based immunosuppressive therapy demonstrates significant advantages over cyclosporin-ME in terms of the severity of acute rejection in SPK transplant patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of acute allograft rejection (AR) on long-term pancreas allograft function is unclear. We retrospectively studied 227 consecutive pancreas transplants performed at our institution between January 1, 998 and December 31, 2009 including: 56 simultaneous pancreas and kidney (SPK), 69 pancreas transplantation alone (PTA); and 102 pancreas after kidney (PAK) transplants. With a median follow-up of 6.1 (IQR 3-9) years, 57 patients developed 79 episodes of AR, and 19 experienced more than one episode. The cumulative incidence for AR was 14.7%, 19.7%, 26.6% and 29.1% at 1, 2, 5 and 10 years. PTA transplant (hazards ratio [HR] = 2.28, p = 0.001) and donor age (per 10 years) (HR = 1.34, p = 0.006) were associated with higher risk for AR. The first AR episode after 3 months post PT was associated with increased risk for complete loss (CL) (HR 3.79, p < 0.001), and the first AR episode occurring during 3- to 12-month and 12- to 24-month periods after PT were associated with significantly increased risk for at least partial loss (PL) (HR 2.84, p = 0.014; and HR 6.25, p < 0.001, respectively). We conclude that AR is associated with increased risk for CL and at least PL. The time that the first AR is observed may influence subsequent graft failure.
    American Journal of Transplantation 02/2013; · 6.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eine langfristige Normalisierung des Zuckerstoffwechsels zur Vermeidung diabetischer Sekundrfolgen ist bei Patienten mit Diabetes mellitus derzeit nur mit -Zell-Ersatz in Form der Transplantation des Gesamtpankreas oder der Langerhans-Inseln mglich. Bei Patienten mit Typ-1-Diabetes und terminaler Niereninsuffizienz ist eine absolute Indikation zur simultanen Pankreas-Nieren-Transplantation gegeben. Die 1-Jahres-berlebensraten betragen dabei fr Patienten 94–100%, fr Nieren 89–92%, fr Pankreas 85–87%. Die hohe Erfolgsrate mit langfristiger Normalisierung des Glukosestoffwechsels fhrt zu einer Stabilisierung oder Verbesserung der Sekundrkomplikationen, zu einer deutlichen Steigerung der Lebensqualitt und zu einer signifikanten Senkung der Mortalitt im Vergleich zu nur nierentransplantierten Patienten. Die Indikationen von Insel- oder Pankreastransplantation sind vergleichbar. Die operative Prozedur ist bei der Inseltransplantation fr den Patienten wesentlich weniger belastend, die Inselisolierung aber methodisch schwierig und aufwndig. Die 1-Jahres-berlebensraten fr Patienten liegen bei 98%, die der Inseln bei 82%, die der Insulinunabhngigkeit bei 42%. Leider sinken die Funktionsraten innerhalb von 5Jahren auf etwa 10%. Die Stammzelltherapie beim Diabetes mellitus wre die definitive Lsung des Problems des physiologischen Insulinersatzes nicht nur fr Patienten mit Typ-1-Diabetes. Sie befindet sich aber noch in einer relativ frhen Entwicklungsphase.The long-term normalization of glucose metabolism – a prerequisite for the prevention of secondary complications in patients with diabetes mellitus – is only possible by transplantation of a whole pancreas or a reasonable number of islets. An absolute indication for pancreas grafting is given in type 1 diabetic patients with end-stage renal disease. The 1-year survival after simultaneous kidney/pancreas transplantation is, according to the international registry, 94–100% for patients, 89–92% for kidneys and 85–87% for the pancreas. The high success rate with long lasting normalization of glucose metabolism leads to a stabilization and/or amelioration of secondary complications, to an increase in quality of life and, most importantly, to a significant reduction in mortality when compared to diabetic kidney recipients. The indications for islet transplantation are similar to those for pancreatic grafting. Islet grafting is only a minor surgical procedure, but islet isolation is difficult. The 1-year survival for the recipients is 98%, for the islets 82% and for insulin-independency 42%. There is a significant decline of islet function to 10% 5years after transplantation. Stem cell therapy would provide a definitive treatment solution not only for patients with type 1 diabetes. So far, this therapeutic option is still at an early stage of development.
    Der Internist 04/2006; 47(5):489-501. · 0.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: A review of recent literature was performed to identify trends and evaluate outcomes with respect to immunosuppression in pancreas transplantation (PTX). Current status. In the past decade, the majority of PTXs were performed with depleting antibody induction, particularly in the setting of either calcineurin inhibitor minimization, corticosteroid withdrawal or both. Maintenance immunosuppression consisted of predominantly tacrolimus (TAC)/mycophenolatemofetil, TAC/mycophenolic acid or TAC/sirolimus with or without corticosteroids. Depending on PTX category, donor and recipient risk factors, case mix and immunosuppressive regimen, the 1-year incidence of acute rejection has decreased to 5-20%. Current 1-year rates of immunological pancreas graft loss range between 1.8 and 6%. Summary: Depleting antibody induction and either TAC/mycophenolatemofetil or TAC/sirolimus maintenance therapy with early steroid withdrawal have become the mainstay of immunosuppression in PTX. However, the development of non-nephrotoxic, nondiabetogenic, and nongastrointestinal toxic regimens is highly desirable to improve quality of life in all solid organ transplant recipients.
    Expert Review of Clinical Immunology 11/2013; · 2.89 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014